文献速递肾癌与肾肿瘤

系统综述与Meta分析:比较不同全身治疗对非透明细胞肾细胞癌的疗效与不良反应

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2016-12-08

该系统综述与Meta分析检索截至2016年3月24日的文献,纳入5项随机对照试验共365例患者,比较转移性非透明细胞肾细胞癌的不同全身治疗。结果显示舒尼替尼在无进展生存期和总生存期方面有优于依维莫司的趋势,但未达统计学显著,两种治疗的相对获益与风险仍不确定。

要点

  • 纳入5项随机对照试验共365例转移性非透明细胞肾细胞癌患者。
  • 舒尼替尼较依维莫司在PFS和OS上有获益趋势,但各研究均未达统计学显著。
  • 两项仅纳入非透明细胞肾细胞癌的研究Meta分析PFS结果不确定(HR 1.30,95%CI 0.91-1.86)。

核心结论

  • 与哺乳动物雷帕霉素靶蛋白抑制剂相比,血管内皮生长因子靶向治疗在PFS和总生存期方面有获益趋势,但未达统计学显著。
  • 这些治疗的相对获益与风险仍不确定。
  • 需要进一步研究,形式为纳入所有相关试验的个体患者数据Meta分析,或一项有足够把握度检测治疗间潜在差异的随机对照试验。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase和Cochrane Library截至2016年3月24日,仅纳入比较性研究,进行偏倚风险和混杂评估。
  • 共纳入5项随机对照试验,合计365例患者;其中3项比较舒尼替尼与依维莫司,1项仅报告非透明细胞肾细胞癌亚组结果而非整个随机队列。
  • Meta分析仅纳入2项仅招募非透明细胞肾细胞癌患者并报告PFS的研究。

主要发现

  • 依维莫司对比舒尼替尼在转移性非透明细胞肾细胞癌患者中HR为1.41(80%CI 1.03-1.92)。
  • 依维莫司对比舒尼替尼在转移性非透明细胞肾细胞癌评估中HR为1.41(95%CI 0.88-2.27)。
  • 依维莫司对比舒尼替尼在转移性肾细胞癌一线和二线治疗疗效与安全性比较中HR为1.16(95%CI 0.67-2.01)。
  • 依维莫司对比舒尼替尼在转移性肾细胞癌一线和二线治疗疗效与安全性比较中HR为1.5(95%CI 0.9-2.8)。
  • 两项仅招募非透明细胞肾细胞癌患者的研究Meta分析PFS结果为HR 1.30(95%CI 0.91-1.86),结果不确定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 三项比较舒尼替尼与依维莫司的研究中,有一项报告的是非透明细胞肾细胞癌亚组结果而非整个随机队列。
  • 各研究显示的趋势均未达统计学显著。
  • 仅两项研究纳入PFS的Meta分析,结果不确定(HR 1.30,95%CI 0.91-1.86)。
  • 这些治疗的相对获益与风险仍不确定。
  • 需要进一步研究,形式为个体患者数据Meta分析或足够把握度的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: While vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. OBJECTIVE: To systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC. EVIDENCE ACQUISITION: Relevant databases including MEDLINE, Embase, and the Cochrane Library were searched up to March 24, 2016. Only comparative studies were included. Risk of bias and confounding assessments were performed. A meta-analysis was planned for and only performed if methodologically appropriate; otherwise, a narrative synthesis was undertaken. EVIDENCE SYNTHESIS: The literature search identified 812 potential titles and abstracts. Five randomized controlled trials, recruiting a total of 365 patients, were included. Three studies compared sunitinib against everolimus, one of which reported the results for non-ccRCC as a subgroup rather than as an entire randomized cohort. Individually, the studies showed a trend towards favoring sunitinib in terms of overall survival and progression-free survival (PFS; Everolimus versus Sunitinib in Patients with Metastatic Non-clear Cell Renal Cell Carcinoma hazard ratio [HR]: 1.41, 80% confidence interval [CI] 1.03-1.92 and 1.41, 95% CI: 0.88-2.27, Evaluation in Metastatic Non-clear Cell Renal Cell Carcinoma HR: 1.16, 95% CI: 0.67-2.01, Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients with Metastatic Renal Cell Carcinoma HR: 1.5, 95% CI: 0.9-2.8), but this trend did not reach statistical significance in any study. Meta-analysis was performed on two studies which solely recruited patients with non-ccRCC reporting on PFS, the results of which were inconclusive (HR: 1.30, 95% CI: 0.91-1.86). Sunitinib was associated with more Grade 3-4 adverse events than everolimus, although this was not statistically significant. CONCLUSIONS: This systematic review and meta-analysis represent a robust summary of the evidence base for systemic treatment of metastatic non-ccRCC. The results show a trend towards favoring vascular endothelial growth factor-targeted therapy for PFS and overall survival compared with mammalian target of rapamycin inhibitors, although statistical significance was not reached. The relative benefits and harms of these treatments remain uncertain. Further research, either in the form of an individual patient data meta-analysis involving all relevant trials, or a randomized controlled trial with sufficient power to detect potential differences between treatments, is needed. PATIENT SUMMARY: We examined the literature to determine the most effective treatments for advanced kidney cancer patients whose tumors are not of the clear cell subtype. The results suggest that a drug called sunitinib might be more effective than everolimus, but the statistics supporting this statement are not yet entirely reliable. Further research is required to clarify this unmet medical need.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Fernández-Pello S, Hofmann F, Tahbaz R, et al. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. Eur Urol. 2016. PMID: 27939075. doi:10.1016/j.eururo.2016.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。